Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enliven Therapeutics (ELVN) Other Non-Current Liabilities (2022 - 2025)

Enliven Therapeutics has reported Other Non-Current Liabilities over the past 4 years, most recently at $103000.0 for Q3 2025.

  • Quarterly results put Other Non-Current Liabilities at $103000.0 for Q3 2025, changed N/A from a year ago — trailing twelve months through Sep 2025 was $103000.0 (changed N/A YoY), and the annual figure for FY2023 was $67000.0, down 89.83%.
  • Other Non-Current Liabilities reached $103000.0 in Q3 2025 per ELVN's latest filing, down from $204000.0 in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $659000.0 in Q4 2022 and bottomed at $6000.0 in Q2 2024.
  • Median Other Non-Current Liabilities over the past 4 years was $209000.0 (2023), compared with a mean of $245700.0.
  • The largest annual shift saw Other Non-Current Liabilities tumbled 98.33% in 2024 before it soared 3300.0% in 2025.
  • Over 4 years, Other Non-Current Liabilities stood at $659000.0 in 2022, then plummeted by 89.83% to $67000.0 in 2023, then plummeted by 91.04% to $6000.0 in 2024, then skyrocketed by 1616.67% to $103000.0 in 2025.
  • Business Quant data shows Other Non-Current Liabilities for ELVN at $103000.0 in Q3 2025, $204000.0 in Q2 2025, and $302000.0 in Q1 2025.